Structure via PubChem · Public domain (PubChem)
etoricoxib
Sign in to saveAlso known as Arcoxia®, MK 0663, MK-0663, 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine, 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl, L791456
Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.
In the Vinony graph
Within Vinony's link graph, etoricoxib is referenced by 491 other articles, and connects out to salicylic acid, non-steroidal anti-inflammatory drug and metamizole sodium.
Vinony files it under 4-(Methylsulphonyl)phenyl compounds, Chloropyridines and Cyclooxygenase-2 inhibitors.
Its subject is documented across 25 Wikipedia language editions.
Chemical data
- Formula
- C18H15ClN2O2S
- Molecular weight
- 358.8 g/mol
- IUPAC name
- 5-chloro-2-(6-methyl-3-pyridinyl)-3-(4-methylsulfonylphenyl)pyridine
- SMILES
- CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
- InChIKey
- MNJVRJDLRVPLFE-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 68.3 Ų
- H-bond donors
- 0
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- Admin. routes
- oral
- Indications
- rheumatic disease, pain, HIV infection, rheumatoid arthritis
via ChEMBL · EBI
Research
1,012 papers- Etoricoxib.Drugs · 2002
- Etoricoxib.Drugs of today (Barcelona, Spain : 1998) · 2004
- [Etoricoxib (Arcoxia)].Revue medicale de Liege · 2004
- Etoricoxib enhances aryl hydrocarbon receptor activity.Toxicology · 2023
- Etoricoxib: a highly selective COX-2 inhibitor.The Annals of pharmacotherapy · 2005
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 358.054
- Has use
- medication
Show 7 more facts
- chemical formula
- C₁₈H₁₅ClN₂O₂S
- World Health Organisation international non-proprietary name
- etoricoxib
- canonical SMILES
- CC1=NC=C(C=C1)C2=NC=C(C=C2C3=CC=C(C=C3)S(=O)(=O)C)Cl
- defined daily dose
- 60
- subject has role
- COX-2 inhibitor
- physically interacts with
- Prostaglandin-endoperoxide synthase 2
- Commons category
- Etoricoxib
via Wikidata · CC0
~4 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Efficacy
- Adverse effects
- Mechanism of action
- Cardiovascular safety and concerns
- References
Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.
It was patented in 1996 and approved for medical use in 2002.
Excerpted from Wikipedia’s “etoricoxib” article, available under the CC BY-SA 4.0 licence.
Available in 25 languages
- Español
- Français
- Deutsch
- Русский
- Italiano
- العربية
- azb
- Bahasa Indonesia
- Bangla
- Central Kurdish
- Finnish
- Greek
- Hebrew
- Hungarian
- Macedonian
- Nederlands
- Norwegian
- Romanian
via Wikidata sitelinks · CC0